- Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell LymphomaLi, Zhiming; Yang, Haiyan; Cen, Hong; Huang, Rui; Cai, Zhen; Gu, Xuekui; Bao, Hanying; Xu, Zusheng; Xu, Zuhong63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA, 2021-12-11 To 2021-12-14.
- Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II StudyLi, Zhiming; Sun, Peng; Cen, Hong; Yang, Haiyan; Huang, Rui; Cai, Zhen; Gu, Xuekui65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Orelabrutinib Plus R-CHOP Regimen in Treatment-Naive Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)Xiao, Yi; Wu, Jiaying; Zhou, Mi; Shang, Zhen; Zhu, Ming65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Phase 2 Search Study:XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
21阅读
